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Abstract
Many patients may present to Emergency Departments (ED) daily for a multitude
of medical issues that may include chest pain, shortness of breath, nausea, vomiting,
elevated troponin levels in the presence of CKD, abnormal serum BUN and creatinine
levels, or an abnormal renal ultra sound. Troponin levels that are elevated within the
presence of CKD with no other signs and symptoms is not concerning for ACS or MI, but
for cardiovascular death and mortality. The purpose of this project was to develop,
create and deliver an educational program designed to increase nursing knowledge of
elevated troponin levels in the presence of Chronic Kidney Disease. A pre-&post-test
design was developed and implemented to measure the nursing staff’s knowledge of
elevated troponin levels in the presence of CKD. The educational program was designed
as a pamphlet that provided information from the literature and relevant clinical
experience about signs, symptoms and the diagnosis of CKD, signs & symptoms of
Acute Coronary Syndrome, (ACS). Twenty-three nurses (25%) completed both the pretest with a mean score of 74.7% with total scores ranging from 40%-90%. Twenty-three
nurses also (25%) also completed the post-test with a mean score of 76.5% with total
scores that ranged from 50%-100% which helped to prove there was an overall increase
in learning, therefore suggesting that nurses’ knowledge on the topic was improved.
Recommendations and implications for APRNs are also discussed.
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Troponin Elevation in Chronic Kidney Disease: An Educational Project
Background/Statement of the Problem
Chronic kidney disease (CKD) affects more than 30 million Americans with
many going undiagnosed (Centers for Disease Control and Prevention, 2017). The
clinical manifestations of CKD are vague and often, the signs and symptoms are
extremely non-specific and can manifest other disease processes. The complications of
CKD include hypertension, cardiovascular disease, hyperkalemia, elevated troponin
levels at baseline (Mayo Clinic 2018). These complications are enormous and
tremendously intimidating, so it is imperative during the initial assessment that providers
identify potential complications.
According to Ozieh et al. (2017), CKD is defined as a decreased glomerular
filtration rate of less than 60 ml/min, or the presence of one or more markers that indicate
kidney damage for three months or greater. CKD is not only burdensome as a medical
disease, it is also very costly with non-dialysis CKD patients amassing a total of 18.2% of
total Medicare expenditures which amounts to approximately 45.5 billion dollars
annually, breaking down to approximately $22,348 per CKD patient annually. Ozich et
al. are the first to examine the costs surrounding CKD and the impact it has on the
healthcare system as a whole.
Patients who present to the emergency department with acute coronary syndrome
(ACS) may have elevated troponin levels. It also important to note is that patients who
are not currently experiencing chest pain and have CKD can also present with troponin
levels that are elevated. Early detection and differential is imperative, so treatment may
begin, which will help to prevent further progression to kidney failure. Medical
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professionals, including doctors, physician assistants, advanced practice registered nurses
(APRNs) and nurses alike, need to emphasize primary prevention and treatment to
preserve and restore health status and stave off disease progression.
Practicing clinicians and nurses alike should be acutely aware that during the
evaluation of patients with CKD, the occurrence of potentially high sensitivity assays
may result due to non-acute coronary syndromes. Clinical and related medical
professionals caring for patients with CKD need to keep in mind the increased risk of
developing ACS or myocardial infarction (MI) directly related to acute ischemic heart
disease in the CKD patient population.
Troponin assays are used to diagnose potential ACS in all patients within the
general population as well as those diagnosed with CKD and chronic renal disease. The
baseline troponin values in patients with CKD will likely be elevated above the ninetyninth percentile of the healthy population despite which troponin assay is utilized. In
patients with CKD, high sensitive assays for both troponin levels for T and I will display
greater than the ninety-ninth percentile when the high sensitivity assays are utilized.
Heart disease is the number one cause of death in the CKD patient population summating
up to 50% of deaths Colbert et al. (2015).
The purpose of this project was to develop, create and deliver an educational
program to improve quality and increase knowledge of emergency department nurses on
the significance of elevated troponin levels in the presence of CKD. The research
question was: Do emergency room nurses understand the relationship with elevated
troponin levels and patients with CKD? An educational project was developed, created,
and delivered to emergency department staff nurses to provide information about
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troponin levels are elevated in patients with CKD without the presence of acute coronary
syndrome (ACS).

Next, the relevant literature review will be presented and discussed.
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Literature Review
A search of the literature was performed using the Cumulative Index to Nursing
and Allied Health Literature (CINHAL) and (PubMed) using the search terms: cardiac
troponin, troponin testing, CKD, estimated glomerular filtration rate, and acute
myocardial infarction. The review of literature was limited to full text articles only,
published in English within the past ten years.
Chronic Kidney Disease
According to Rosenberg (2016), CKD is defined as the presence of kidney damage.
Kidney damage is detected as excretion of urinary albumin of greater than 30 mg/day or
its equivalent. A second identifier would illustrate decreased kidney function as an
estimated glomerular filtration rate (eGFR) of less than 60ml/min/1.73m2 for a period of
at least three months or more regardless of what caused the condition. The damage or
reduction of kidney function delineates CKD from an acute kidney injury (AKI).
Chronic kidney disease is classified into stages which guide providers on how to
manage, locate any potential risks, guide treatment to cease progression, and highlight any
potential complications that may arise from the progression of the disease. Treatment
involves reversing the causes of renal failure, preventing, or stunting the progression of
renal disease, treating complications of renal disease, adjusting pharmacotherapy when
appropriate to the current level of eGFR, and identifying and preparing the patient when
renal replacement therapy will be mandatory (Rosenberg, 2016).
Acute Coronary Syndrome
Miller & Granger, (2016) state that the chief complaint of chest pain is responsible
for approximately 6 million annual visits to emergency departments in the United States.
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Acute Coronary Syndrome (ACS) is responsible for 12 to 15% of those cases. ACS is a
functional term applied to patients where there is an indication of myocardial ischemia or
myocardial infarction (MI). There are three different types of ACS: unstable angina, nonST elevation MI, and ST elevation MI. ST elevation and non-ST elevation MI, diagnosable
if elevated troponin levels are present, which will typically rise and fall before, during, and
after an event. Unstable angina is classified as myocardial ischemia with no elevation in
biomarkers like troponin. Most often the clinical diagnosis is made based on the patient’s
story, history of present illness, thorough physical examination, current electrocardiogram,
evaluation of basic lab work, and or evidence of ischemia with stress testing (Miller &
Granger, 2016).
The immediate focus should be on treatment, because early intervention leads to
the best outcomes (Miller & Granger, 2016).

Upon presentation to the emergency

department, an initial 12 lead EKG should be obtained within ten minutes, and continuous
telemetry monitoring initiated. Next, a history and physical exam to correlate with current
signs and symptoms exhibited. Laboratory tests should be ordered, to include troponin,
electrolytes, bun, creatinine, and complete blood count. A chest x-ray is standard in this
patient population, as it can be an asset with differential diagnosis. A risk stratification
assessment of the patient presenting with these signs and symptoms is conducted (Miller
& Granger, 2016).
Troponin Sensitivity and the Correlation to CKD & ACS
Troponin is the preferred biomarker to diagnose acute myocardial infarction
which may or may not be present with presentation of ACS. Troponin is a
macromolecular complex that consists of three polypeptides closely intertwined and are
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actively related to the contraction of heart muscle. The three types of troponin are cTnC
which are responsible for calcium binding, cTnI for inhibiting actin-myosin collaboration
and lastly cTnT which represents tropomyosin that is required to enable contraction
(Mohammed & Januzzi, 2010).
According to Mohammed & Januzzi, (2010), troponin is discharged when
irreparable damage to the myocyte is about to occur. Quantifiable release of troponin
begins typically 4-6 hours after cell death, and crests at approximately eighteen to
twenty-four hours. Troponin levels can remain detectible in serum levels for the
subsequent fourteen days post event. Typically, troponin levels are drawn at specific
intervals every three, six, or eight hours depending on policy of each individual
institution (Mohammed & Januzzi, 2010).
The elevation of troponin can occur without the presence of ACS Mohammed &
Januzzi, (2010). The authors identify a multitude of causes for the potential rise in
troponin without the presence of ACS in their review that encompassed mainly
quantitative research from eight studies. The elevation should be thoroughly investigated
and not be discarded as a “false positive.” The authors concluded that the adoption of the
99th percentile of a healthy patient population to diagnose MI. With newly available
ultra-sensitive blood testing methods in place and the increased use in patient care, the
conclusion will be an increase in troponin levels in patients presenting without the
presence of ACS. The authors caution providers that the elevation of troponin does not
identify the mechanism of myocardial injury and addresses the importance of utilizing
differential diagnosis for the elevated troponin value.
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Wang, et al. (2017) conducted a review of current literature searching several
databases for evolving biomarkers now available, and those that are considered up and
comers within the realm of myocardial necrosis. The authors reviewed studies on high
sensitivity reactive protein (hsCRP) and noted an association between elevated
inflammation levels and potential cardiac events with hsCRP being a predictor of these
events. The researchers reviewed 55 studies and analyzed other evolving biomarkers that
included natriuretic peptides, troponins, uric acid, and galectin-3 all of which show
correlations with cardiovascular events. Cardiac troponin I (cTnI) and T (cTnT) are
proteins that are exclusive to myocardial function and are extremely sensitive biomarkers
that signify damage to the myocardium upon their release (Wang et al., 2017).
Furthermore, troponins are classified as the most sensitive biomarkers indicating
myocardial injury perpetually more than its creatinine kinase counterpart. The
researchers looked at a variety of biomarkers, including troponin, natriuretic peptides,
and amino acids, that may be indicative of myocardial injury. The authors conclude that
more research is needed to further apply the newer biomarkers that will proliferate
rapidly. These biomarkers should not be exclusively acted upon, rather that they be
utilized in conjunction with other clinical information to include thorough history,
physical, and risk stratification along with radiographic findings to accurately treat and
diagnose patients.
Van der Linden et al. (2016), conducted a meta-analysis aimed to quantify and
compare the relationship between cTnT and cTnI troponin levels with cardiovascular and
all-cause mortality in the general population. The researchers’ analysis included 2585
reviewed citations, 11 studies, with data on 65,019 participants. Random pooling
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illustrated substantial relations between basal cardiac troponin levels and all-cause
mortality. There was a significance in the difference of the meta-regression analyses for
cardiovascular mortality but showed no statistical difference for all-cause mortality
(P<0.01). The authors concluded that an elevation of baseline cTnT and cTnI show
strong links for an increased risk of cardiovascular and all-cause mortality during follow
up in the general population. The correlation is even stronger for cardiovascular
mortality than all-cause mortality, but that troponin T is stronger than troponin I but will
require further research.
Jaffe & Morrow (2017) delineate between the use of cTnI, and cTnT. The authors
describe the assays as being sensitive, and that higher sensitive assays are available, but
not in the United States. Jaffe & Morrow highlight guidelines for troponin testing and list
a variety of clinical conditions where it is essential to include possible acute myocardial
infarction, ACS, after revascularization therapy, and after myocardial infarction which
can help determine the magnitude of the infarct and prognosis. The initial troponin level
is drawn upon presentation to the health care system and typically re-drawn and
compared to the initial result within three to six hours depending on facility policy. In
the general population, there is even a small window where elevated troponins can be
measured without an acute event, and the typical rise and fall of troponin will not be seen
in this population. Troponin is the preferred biomarker to aid in the diagnosis of
myocardial cell damage or death as seen with myocardial infarction. Values that register
above the 99th percentile in the healthy population and in conjunction with clinical
information and electrocardiographic changes seen on EKG may be because of structural
heart damage without any acute presentation. The more sensitive the assay, the more
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vital to investigate if the troponin level has changed which can assist in the confirmation
of myocardial infarction. The recommendation of the authors is to use troponin as
preference to creatinine kinase MB both for diagnostic and prognostic means, as it is not
cost-effective care to obtain both.
Gibson & Morrow (2017) discuss the possible causes of troponin release in the
absence of ACS. The authors found in one study that several patients with specific
conditions may cause patients to present with elevated troponin levels to including
tachycardia (28%), pericarditis (10%), heart failure (5%), no clear precipitating event
(47%), and even participating in strenuous exercise, (10%). Several other studies were
included in the review to include an additional 6 studies with a combined sample size of
54,000 study participants and confirmed that a small amount of elevated troponin levels
can be linked to structural heart disease in the absence of any acute process. When these
authors reviewed troponin levels in patients with stable ischemic heart disease, an
additional 6 studies with a combined sample size of 19,560 it was found that elevated
troponin levels were associated with irregularities of cardiac structure and functionality
nearly 37% higher, and in cases of critical illness a worse prognosis was highly probable.
The authors’ state that troponin elevation without ACS is a significant finding and that
further work up may be justified solely on that finding. Uncovering the underlying cause
of the troponin elevation through a comprehensive history and detailed physical
examination, which can illuminate conditions, like myocarditis, pericarditis, cardiac
contusion, sepsis, pulmonary embolism, and heart failure, is essential.
Gibson & Morrow, (2017) state there is currently no data from randomized trials
that indicate that there is a reduction of risk from current therapeutic regimens for
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patients with troponin elevations without the presence of ACS. The authors recommend
the use of aspirin unless contraindicated because it is generally harmless, though the use
of antiplatelet and antithrombotic medications are not generally used in the management
of elevated troponin. Lastly, troponin is an essential part of the decision-making process
in the setting of other illnesses like pulmonary embolism, and cardiotoxic
chemotherapeutic medication administration.
Chronic Kidney Disease and its Relationship to Coronary Heart Disease
Matsushita et al., (2016) conducted a systematic review in order to clarify the
clinical guidelines on the application of predicting the cardiovascular risk of those
diagnosed with CKD. Matsushita et al completed an individual level meta-analysis
where a creatinine based glomerular filtration rate (eGFR) and albuminuria were used as
measures for CKD and applied the precise statistical methods across 24 cohort studies.
The meta-analysis showed that eGFR and albuminuria help to improve the prediction of
risk of getting cardiovascular disease over outdated risk factors to include coronary heart
disease, eGFR, and high-density lipoprotein (HDL) for overall mortality and heart failure.
In summary, the two key measures eGFR and albuminuria improve CVD risk estimates
beyond traditional risk factors. It is felt that clinical guidelines may require updates
about how or when to integrate CKD measures and other mentioned biomarkers in
prediction of CVD based on outcomes desired in a specific population and the
accessibility of needed biomarkers in the CKD population Matsushita et al., (2016).
Sud & Niamark (2015) conducted a systematic review with the purpose of
advancing the understanding of cardiovascular outcomes in patients diagnosed with
advanced or progressive CKD. The authors reviewed data from five articles from the
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United States and Canada with a focus on describing the dynamics of cardiac death in
patients with CKD. The results of the review showed that when eGFR is below
60/ml/min, cardiovascular disease is the most common cause of death (Sud & Niamark,
2015). Patients with advanced CKD are excluded from clinical trials for heart failure
therapy. The researchers conclude that the risk of sudden cardiac death is elevated in
patients with systolic heart failure as ejection fraction decreases. Renewed calls for
increased coordination of efforts among nephrologists and cardiologists to start
randomized controlled trails devoted solely to patients with advanced CKD can help to
improve outcomes and understanding of the disease pathophysiology (Sud & Niamark,
2015).
Sarnack, Gibson & Henrick (2015) conducted a systematic review on the
correlations between CKD and coronary heart disease. A diminished glomerular
filtration rate and increased proteinuria raise the potential to develop cardiovascular
disease in populations with elevated cardiovascular risk. The authors reviewed a
combination of ten studies which varied from meta analyses, two randomized controlled
trials, and one longitudinal study. Sarnack, Gibson & Henrick, (2015) recommend a
thorough risk stratification assessment with the addition of statin medication to reduce
cholesterol in patients with eGFR less than 60ml/min per 1.73 m2. A commitment to the
reduction of hypertension in patients with proteinuria and CKD with the use of an
angiotensin blocker is recommended (Sarnack, Gibson & Henrick 2015). The studies
concluded that decreased eGFR and increased proteinuria increase the risk of developing
cardiovascular disease. In addition, patients diagnosed with CKD will require drug
dosage adjustments because of the potential for drug related adverse effects. Patients
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diagnosed with CKD present with traditional and nontraditional risk factors that
contribute to the development of cardiovascular disease such as hypertension, smoking,
diabetes, and elevated cholesterol levels (Sarnack, Gibson & Henrick, 2015).
Cardiac Biomarkers in CKD without ACS
Lamb et al., (2007) conducted an observational cohort study that enrolled two
hundred and twenty-seven Caucasian patients at East Kent Hospital located in Oxford,
United Kingdom. The purpose was to evaluate the prevalence of increased cTnI
concentrations in patients diagnosed with CKD to determine clinical associations and the
prognostic importance of increased cTnI Ultra assays compared against cTnT and the
original cTnI standards. Participants were grouped into CKD stages according to the
eGFR using estimated glomerular filtration rate (eGFR) and the simplified Modification
of Diet in Renal Disease Study formula. In conclusion, the researchers illustrate that
cTnI concentrations are elevated in patients with CKD, although the cause is still unclear
(Lamb et al., 2007).
deFilippi et al., (2012) conducted a multicenter observational study to analyze the
association between high sensitivity (cTnT), and (cTnI), in patients with cardiovascular
disease and stable CKD. The study was conducted in outpatient nephrology clinics at
three hospitals. The sample size was 148, all males, ages 18-71 years who had prior
myocardial infarction, coronary revascularization, glomerular filtration rate less than
60ml/min, an echocardiography measuring left ventricular ejection fraction, and CT scan
to assess level of coronary artery calcification. Patients with CKD had a high sensitivity
assay troponin T (deFilippi et al., 2012). The association of high cardiac troponin assays
and renal function, specifically the troponin T marker, was significantly higher than that
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of its troponin I counterpart (deFilippi, et al., 2012). Conclusively, when troponin is used
to confirm suspected acute coronary syndromes in patients diagnosed with CKD, the
baseline value should measure above the 99Th percentile of the healthy population.
Balamuthusamy et al., (2007) conducted a retrospective chart analysis with a
sample size of 108 patients that underwent coronary angiography. The study took place
over a period of three years at the Mount Sinai Medical Center located in Chicago,
Illinois. The goal was to analyze sensitivity and specificity of cardiac troponin I in
detecting obstructive coronary artery disease in the African American population
diagnosed with renal insufficiency. Participants were of African American decent,
diagnosed with acute coronary syndrome and had some degree of renal failure, namely
creatinine levels elevated >1.1mg/L. The authors found that cTnI has lower sensitivity
and specificity in patients with renal failure undergoing hemodialysis secondary to
changes in elimination. They also conclude that other methods should be used to arrive
at the correct diagnosis and appropriate risk stratification of patients with non-ST
elevation myocardial infarction. Further research is essential to understand results of
traditional biomarkers used for diagnostic reasons (Balamuthsamy et al., 2007).
Colbert et al., (2014) conducted a review that aimed to summarize fifty-one
completed studies of varying design primarily cross sectional and longitudinal study
designs with one study being a case control design. The researchers reported associations
among used cardio biomarkers like cTnT, B-type Natriuretic Peptide (BNP), NT-ProBMP, left ventricular mass index, coronary artery calcium score (CAC), carotid intimamedia thickness (cIMT), and clinical outcomes in patients with CKD in patients not
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undergoing maintenance dialysis to highlight the strengths and limitations of data that is
currently available for use with prognostication.
Colbert et al., (2014) conclude their review stating that there are current
knowledge gaps and more data is needed before these biomarkers can be reliably used in
the population of patients with CKD. Colbert et al., (2014) state that some of the
observational studies reporting associations between cTnT and a decline in eGFR in nondialysis patient populations with CKD may be affected by a decreased renal clearance in
the setting of advanced CKD. While the results signify that these biomarkers can be used
to forecast future cardiovascular events in asymptomatic patients with CKD, additional
research is needed to confirm a standardized cutoff value for biomarkers as diagnostic
tests for patients with CKD.
Prognostic Value of Cardiac Markers in CKD
Michos, et al., (2014) conducted a large systematic review & meta-analysis with
the purpose to review literature on troponin testing in patients with CKD without the
presentation of ACS. Approximately 98 studies in 105 publications met the inclusion
criteria. Michos et al., (2014) state that further work is needed to determine the
mechanism for the link between elevated troponin levels and undesirable outcomes. It
was also established by these researchers that more research is needed to investigate
whether it is solely the troponin level alone, or its presence in combination with other
biomarkers that can improve the way CKD patients are positioned in higher and lower
risk groups in existing clinical models. The question still remains of how patients with
CKD with risk stratification performed by troponin level for dialysis patients with no
presentation of ACS their clinical course of treatment. In the conclusion of this review,
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the researchers show that elevated troponin levels reveal an association of a worse
prognosis in patients with CKD not experiencing ACS. For patients with CKD with no
indication of ACS, elevated troponin levels remain potent predictors of mortality, and
currently support the current U.S. Food and Drug Administration position that measuring
serum troponin levels is an appropriate risk stratification tool in this patient population.
Bueti et al., (2006) completed a study utilizing a retrospective cohort design that
enrolled a total sample size of 149 at St. Boniface General Hospital, Winnipeg, Canada
that aimed to examine the association between troponin I levels and 30-day outcomes.
All patients were evaluated according to their chief complaint, risk factors for cardiac
disease, initial troponin level, and any other major cardiac event to include MI,
cardiovascular death, or coronary revascularization. Bueti et al., (2006) determined that
the troponin level was commonly analyzed in acutely ill patients that presented to the ER.
The results showed that troponin I was associated with an adverse 30-day outcome
despite the clinical presentation.

The chief concern or nature of presenting complaint

was not helpful in determining if a major cardiac event (MCE) was going to occur within
30 days. It was found that troponin I with a level of > 0.3 ng/L was strongly correlated to
MCE, in fact a level of greater than >2.0 supported the data and was predictive of MCE
>25% of the time. Troponin level elevated above >0.3 are clinically significant in
patients undergoing dialysis regardless of their clinical presentation.
In a pilot study conducted by Sukonthasarn & Ponglopisit., (2007) researchers
aimed to find the diagnostic level and rising pattern of cardiac troponin T (cTnT) with
patients diagnosed with chronic renal dysfunction presenting with acute myocardial
infarction. The study design was a pilot cross sectional study with a sample size of 46
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that compared troponin T levels in adult patients with chronic renal dysfunction that were
subsequently admitted and later found to have acute myocardial infarction with age and
sex controls and non-coronary diagnosis. Researchers concluded that troponin levels of
0.1 ng/ml drawn in the first 24 hours of admission proved to be diagnostic for AMI in
patients with chronic renal dysfunction. Participants were then redrawn at subsequent
intervals 6, 12, and 24 hours post initial draw. Sensitivity and specificity of troponin
levels were greater if chronic renal dysfunction patients were excluded.
Relationships between Elevated Cardiac Markers in CKD without ACS
Alam et al., (2013) authored a research article that aimed to examine the
association of elevated troponin I levels in stable patients undergoing maintenance
hemodialysis therapy with cardiac-specific mortality, and to distinguish if any increased
risk was autonomous of inflammation status. The design utilized a cohort observational
study, plasma troponin I levels were drawn with routine pre-dialysis lab work with C
reactive protein. All patient outcomes were closely monitored and determining all deaths
as cardiac or non-cardiac.
The study’s design was that of an observational single-center cohort with a
sample size (N=133), featuring participants classified as chronic, stable non-hospitalized
hemodialysis patients where monitoring took place for a three-year period beginning in
July/August 2009 and followed until July of 2012. The blood tests were drawn in the
hospital’s hemodialysis unit and analyzed in the hospital’s central laboratory. Alam et
al., (2013) conclude that elevated troponin I levels provide prediction of cardiac risk.
Elevated troponin levels are life-threatening, and it is essential to get to the underlying
pathophysiological progressions that lead to it. The study adds to the research currently
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available to back more extensive tactics to conduct more thorough cardiac risk
stratification in hemodialysis patients to include stress testing, targeted risk stratification,
functional cardiac testing, or conventional medical treatment.
Chen et al., (2013) conducted a study that aimed to assess the results of
troponin I in non-acute coronary syndrome patients with a diagnosis of CKD. The study
was constructed using a sample size of N= 293 patients with CKD and had a troponin
level drawn. The design of the study was shown through retrospective chart review over a
two-year period. The results of the study concluded that almost half, 43.34% of the nonacute coronary syndrome patients with CKD, and 26.03% of the patients without ACS
and CHF have elevated levels of troponin I. Furthermore, congestive heart failure is
linked to elevated troponin levels without the presence of ACS patients with CKD.
In a study, Li, et al., (2015) performed a meta-analysis through a systematic
search of studies pertinent published by November 2013 in the MEDLINE database.
Studies were included based on 5 inclusion criteria that included published in English,
had randomized control trials or observational study design, patients diagnosed with
CKD defined as having eGFR <60/mL/min per 1.73m2, had stated long term all-cause
mortality or cardiovascular mortality of CKD, patients who had elevated levels of Creactive protein (CRP), and had estimates of risk ratios (RR’s) or Hazard ratios (HR’s)
within a 95% confidence interval. Exclusion criteria included animal studies, autopsies,
phantom studies, and myocardial infarction. A total of 828 articles were returned and
after excluding many, it was decided that 20 would be included in the C-reactive protein
(CRP) analysis, and 17 would be included within the troponin analysis.
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In conclusion, the meta-analysis shows elevated troponin levels and CRP are
largely associated with increased risks of all cause and cardiovascular mortality in
patients diagnosed with CKD. Future studies with more strict calibration, long term
monitoring, and more complex design representing large and representative populations
are essential to the investigation of more complex risk stratification of CKD patients.
Next, the Theoretical Framework guiding this project will be introduced and
discussed.
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Theoretical Framework
Two separate frameworks were identified and discussed for use in this project.
The Adult Learning Theory was developed by Malcom Knowles in the beginning of the
1970’s and will assist in the development and delivery of an educational program.
Knowles’ learning theory was created specifically for adults and is largely formulated on
six individual principles: the need to know, the learners’ self-concept, the role of the
learner’s experiences, the learners’ readiness to learn, orientation to learning, and lastly
the learners’ motivation to learn (Knowles, Holton, & Swanson, 2011). Adults are
intuitive and seek what the reason is before learning something new. Self-concept is
explained as being responsible for their own decisions and being capable of selfdirection. The role of learners’ experiences relies on experimental techniques that delve
into the experience of the learner utilizing experiences like group discussions, simulation
exercises, and peer to peer helping of one another. Readiness to learn highlights the
learners’ the ability to accomplish what essentially needs to be done so knowledge can be
attained. Orientation to learning occurs based on the perception that lessons being taught
will help them to problem solve with real life situations. Motivation directly relates to
the adults’ responsiveness to internal like increased job satisfaction, and external
motivators like promotions and better salaries (Knowles et al., 2011).
Malcom Knowles Adult Learning theory is applicable to this project primarily
with the principle of Andragogy which translated means “Man Leading.” The use of
Knowles Adult Learning Theory will allow nurses to learn at their own pace, at a time
and place convenient to them.

Adults are primarily lifelong learners and typically

participate actively especially in the field of medicine, knowing it will translate into being
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better prepared healthcare workers. Nursing is no different and requires individuals to
keep up with current best practices to maintain core competencies with specificity to their
nursing specialty. If a nurse discovers a lack of experience with a skill or procedure, they
will typically obtain the information needed to complete the task via textbook, resource
material or from another college. Registered nurses are more compelled to learn when it
will directly benefit their way of clinical practice (Knowles et al, 2011).
The Kellogg Foundation’s Logic Model was implemented to assist in the
preparation, execution, and evaluation of the educational program that was developed by
the researcher. According to the Kellogg Foundation (2004), the Logic Model provides a
systematic and visual way to present and share the understanding of relationships among
the resources available, operate the program, the activities planned, and the change or
results anticipated to achieve. The Logic Model is comprised of five components that are
visually depicted on a diagram and are read left to right. The five components included
are resources/inputs and activities which are fall under the umbrella of the researchers
planned work. The remaining components fall under the researchers intended results and
include outputs, outcomes, and impact.
The Logic Model will be utilized in this project implementation. The inputs in
the project would be support from emergency department management and the Chief
Nursing Officer. The activities would be the educational information provided to ER
nurses in both the poster displayed and the pamphlet emailed to participants. The
outcomes associated with the project would be an overall knowledge increase after the
informational program has been delivered. The impact of the project would be an
increased awareness and understanding for elevated troponin levels in the setting of CKD
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without ACS. Learning will be assessed by the administration of a 10 question pre-and
post-test. The Logic model is illustrated below (Figure 1).
Figure 1. The Logic Model retrieved from https://www.wkkf.org/resourcedirectory/resource/2006/02/wk-kellogg-foundation-logic-model-development-guide

Next, the methods used to conduct this project will be presented and discussed.
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Methodology
Purpose/Question:
The purpose of this project was to develop, create and deliver an educational
program to improve quality and increase knowledge of emergency department nurses on
the significance of elevated troponin levels in the presence of CKD. The research
question was: Do emergency room nurses understand the relationship between elevated
troponin levels and patients with CKD?
Design:
An educational program was developed of to determine ED nurses’ knowledge on
the significance of elevated troponin levels in the presence of CKD. A quantitative pretest and post-test format (Appendix A) was instituted to adequately measure the
emergency department nurses’ knowledge of elevated troponin levels in the presence of
CKD.
Site:
The proposed project was conducted at a local community teaching hospital with
359 acute care beds located in Warwick, Rhode Island. The Emergency Department has
60 beds with an annual patient census of approximately 70,000 and is Rhode Island’s
only Level 2 Trauma Center.
Sample Size/Participants:
The study sample was selected using a purposive random sample. The total
possible participants was 92 nurses. The target proposed sample size consisted of one
third or 33% registered nurses actively working within the emergency department to
include full time, part time, per diem and traveler status (n=32). Inclusion criteria
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consisted of staff registered nurses (RN’s) assigned to the ER, with no exclusions based
on age, gender, ethnicity, educational level, or employment tenure. Exclusion criteria
was nurses floating to the emergency department for supplemental coverage, or those
RNs not directly assigned to the ED, and non-nursing personnel.
Procedure:
Emails were sent to the Chief Nursing Officer and the Director of Emergency
Services to garner support for the proposed project. Email responses were received by
this author from the Chief Nursing Officer (Appendix B) as well as the Director of
Emergency Services granting permission for the project, on a condition that the
Institutional Review Board (IRB) at Kent County Hospital also approved it. IRB
applications were submitted to both Kent County Hospital and Rhode Island College.
Kent County Hospital IRB determined that this project was exempt from IRB approval
(Appendix C). Rhode Island College IRB approved this application.
The anticipated timeframe for the project was sometime in February and March of
2018 in the Emergency Department at Kent Hospital in Warwick, Rhode Island. An
informational email (Appendix D) and email script (Appendix E) was sent to the Director
of Emergency Services, shift managers, as well as all nursing staff to explain the purpose
of the project before the educational information was delivered. The staff was informed
that participation is voluntary. An incentive for participation was a gift card in the
amount of twenty-five dollars. A time allotment of two weeks was allowed to take the
pre-test (Appendix A) which was anonymously completed via an online survey platform
called Survey Monkey. Reminder emails (Appendix E) were sent out to potential
participants five and ten days after the pre-test was sent. The educational pamphlet
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(Appendix F) was developed with the help of the literature and the clinical experience
and expertise of this program developer. The use of educational pamphlet (Appendix F)
allowed the material to be viewed via email or in person as it was placed in the break
room for staff to review during breaks or meal times. Reminder emails to review the
educational pamphlet (Appendix F) and complete the post-test were sent five and ten
days after the educational pamphlet (Appendix F) was sent. The pre-& post-test was
anonymously completed via an online survey platform called Survey Monkey one week
after potential participants had time to review the educational pamphlet (Appendix F).
The pre-and post-tests (Appendix A) were analyzed for an overall increase in knowledge
across the board for all nursing staff that participated. The learning objectives are listed
below in Table 1.
Table 1.
Objectives

Content

The Nurse will be able to demonstrate
knowledge pertaining to signs and
symptoms of CKD.
The Nurse will be able to identify risk
factors for CKD.

Common Signs & Symptoms of CKD

The Nurse will be able to describe how
CKD is diagnosed.

Diagnosis of CKD

The Nurse will be able to demonstrate
understanding of common signs and
symptoms of ACS
The Nurse will be able to state risk factors
for ACS.

Common Signs & Symptoms of ACS

The Nurse will be able to identify both
normal & abnormal troponin levels

Normal Troponin Levels

The Nurse will be able to explain the
significance of elevated troponin levels in
the setting of CKD

How the nurse should respond with
elevated troponin levels in the presence of
CKD, but with the absence of Acute
Coronary Syndrome

Risk Factors for CKD

Risk factors for Acute Coronary Syndrome
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Measurement:
A pre-test and a post-test were developed based on the information to be delivered
(Appendix A). The project consisted of a design of quantitative data encompassed in the
survey. The project compared nurses’ responses from the pre-test-to the post-test which
occurred after information on the topic has been presented. Comparison was
accomplished through standard statistical analysis to include total scores, mean scores,
and percentiles taken directly from the number of respondents. The pre-test and post-test
(Appendix A) consisted of the same exact identical questions and was piloted with Rhode
Island Collage Master’s Program students for accuracy, clarity, and ease of understanding
prior to use within the educational program There was no identifiable demographic data
collected.
Data Analysis
The data collected from the pre-tests and post-tests (Appendix A) were analyzed
using descriptive statistics to include total scores, mean, and percentages.
Next, results will be presented and discussed.
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Results
Out of the possible total number of 92 RN’s working within the Emergency
Department at the time of the development and implementation of this informational
program, 23 respondents completed the pre-test (Appendix A) (25.0 %). The respondents
were categorized by educational level, and years of experience. Ten respondents held
associate degrees (43.5 %) and 13 held bachelor’s degrees (56.5 %). No RN’s with
diplomas or advanced degrees responded in the pre-test. Of the respondents, there were
three nurses with less than 5 years’ experience (13.0%), four nurses with between 6 and
10 years’ experience (17.4%), eight nurses with between 11-15 years of experience
(34.8%), and eight nurses with over 20 years’ experience (34.8%).
Nurse participants in the program completed a pre-test, and post-tests (Appendix
A). The question types were multiple choice or select all that apply. The completed pretests scores ranged from 40% to 90% with a mean score of 74.7%. Roughly 21.7% of the
nurses (n=5) scored ninety percent on the pre-test, 30.4% (n=7) scoring in the eightieth
percentile, 30.4% (n=7) scoring in the seventieth percentile, 13.0 (n=3) percent scoring in
the sixtieth percentile, and lastly 4.3% (n=1) scoring in the fortieth percentile.
The number of nurses that completed the post-test (Appendix A) was also (n=23).
The respondents were categorized by educational level, and years of experience. Those
with associate degrees were 4 respondents, (17.2%), bachelor’s degree, 18 respondents
(78.3 %). One respondent has a master’s degree which represented (4.4%). No
respondents with diploma certificates responded to the post test. Of the respondents there
were eight nurses with less than 5 years’ experience (34.8%), five nurses with between 6
and 10 years’ experience (21.8%), one nurse with between 11-15 years of experience
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(4.4%), and eight nurses with over 20 years’ experience (34.8%). All the respondents got
question 3 incorrect which asked how CKD is diagnosed and was a multi response
question requiring participants to pick more than one answer.
The completed post-test (Appendix A) scores ranged from 50% to 100% with a
mean score of 76.5% therefore demonstrating an overall increase in learning. Two of the
questions (questions 4 & 5) asked the participants if they could identify normal
glomerular filtration rate in a healthy adult and risk factors for CKD. There was no
change in the score on these questions. One question of note experienced a significant
decline from the pre-test to the post-test (question 11). The question asked participants
what the significance of an elevated troponin level meant in the presence of CKD with
the absence of presenting notable cardiac symptoms. Participants responded correctly
52% of the time (n=12) on the pre-test and only 17% (n=4) on the post-test regardingM
question 11. Question 3, which asked how CKD is diagnosed improved from 0% correct
on the pre-test to 65% (n=15) correct on the post-test. Most of the nurses were able to
correctly identify the appropriate signs & symptoms of ACS in both the pre-test 91.3%
(n=21) and post-test 95.6% (n=22).

Pre & Post Test Results
120%
100%
80%
60%
40%
20%
0%
Question Question Question Question Question Question Question Question Question Question
3
4
5
6
7
8
9
10
11
12
Pre Test

Post Test

Figure 1. Pre-Test & Post-Test Results by Question, n= 23
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Next., the summary and conclusions will be presented and discussed.
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Summary and Conclusions
Chronic kidney disease (CKD) affects more than 30 million Americans with
many going undiagnosed (Centers for Disease Control and Prevention, 2017). The
clinical manifestations of the disease are common and often the signs and symptoms are
extremely non-specific and can manifest other disease processes. The complications of
CKD are vast, and tremendously intimidating, so it is imperative during the initial
assessment that providers identify potential complications. CKD is not only burdensome
as a medical disease, it is also very costly with non-dialysis CKD patients amassing a
total of 18.2% of total Medicare expenditures which amounts to approximately 45.5
billion dollars annually, breaking down to approximately $22,348 per CKD patient
annually.
A review of current relevant literature was conducted, and models were selected
to guide this project to include the Logic Model, and The Adult Learning Theory. The
purpose of this project was to develop, create and deliver an educational program to
improve quality and increase knowledge of emergency department nurses on the
significance of elevated troponin levels in the presence of CKD.
The design was the development of an educational program to determine ED
nurses’ knowledge on the significance of elevated troponin levels in the presence of
CKD. A quantitative pre-test and post-test format (Appendix A) was instituted to assess
the emergency department nurses’ knowledge of elevated troponin levels in the presence
of CKD. The twelve question pre- & post-test (Appendix A) was developed by this
program developer and was piloted to demonstrate ease of use and understandability. ER
nurses were asked to complete a pre-test, read an educational pamphlet (Appendix F) and
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then take a post-test. The pre and post-test (Appendix A) were distributed through online
survey platform of Survey Monkey. An invitation with a link to the survey was emailed
nurses via their work email (Appendix E). After the pre-test was completed, an
educational packet was emailed, and a hard copy was placed on bulletin boards in the
break room within the emergency department for the nurses to review at their
convenience.
The identified target population for this educational program was 92 nurses who
actively work in the Emergency Department at Kent County Hospital in Warwick, Rhode
Island. A total number of (n=23) or 25% completed both the pre-test and post-test with
mean scores of 74.7 and 76.5 respectively. One question of note experienced a
significant decline when the pre-test was compared to the post-test (question 9).
Question 9 asked participants the what significance of an elevated troponin level meant in
the presence of CKD, with the absence of presenting notable cardiac symptoms.
Participants responded correctly 52% of the time (n=12) on the pre-test compared to just
17% (n=4) on the post-test. The most improved score came on question (question 5)
which refers to how CKD is diagnosed. On the pre-test, all of the nurses thought that
CKD was diagnosed analyzing serum BUN and Creatinine results, not realizing there are
two other diagnostic tools that aid in the diagnosis which are renal ultra sounds, and
microalbumin levels.
Limitations to the project included a low response rate. The goal was to have 33%
of the possible 92 nurses respond (n=33). The response rate was only 23%. The lack of
participation can potentially be tied to an increase in patient acuity, census and missed
meal breaks at the time of implementation, and as a result a lack of time to complete the
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pre-test, educational packet, and the post-test. Another identified limitation was lack of
time to complete the pre-test, educational packet, and post-test which resulted in the
initial allotment of two weeks to be extended into three weeks to garner the most
participants. The method of announcing the project could be identified as a potential
limitation. Nurses receive countless emails daily and the possibility exists that emails
about this program were skipped over or deleted in error even though there was
enthusiasm and support for the educational program. Many nurses do not check their
work email from home. Respondents in the post-test included one APRN and four
Associate degree nurses which could have altered the results. Another limitation
involved some participants not completing all of the questions on the pre or post-test
which resulted in those responses having to be discarded.
The main objective of this educational program to improve knowledge of nurses
in the emergency department was met. There was an increase in overall learning by about
1.8% as illustrated in the pre-& post-test mean scores.
Next, Recommendations and Implications for Advanced Nursing Practice will be presented
and discussed.

32
Recommendations and Implications for Advanced Nursing Practice
Advanced Practice Registered Nurses (APRN’S) now more than ever will be
called upon to be a more active player in the United States Healthcare System as a change
agent and leader when it comes to advocating for patients and providing care. For
APRN’s working in any setting, it will be essential for them to discern between the
patient that presents with an elevated troponin in the presence of CKD versus the patient
that presents with an elevated troponin and the constellation of signs and symptoms
concerning for ACS with or without the presence of CKD. The APRN will begin to
stratify the patient’s risk more comprehensively to identify potential incidences of
increased risk like that of the troponin level, but the emphasis of future research should
be placed on understanding the pathophysiological processes that precede troponin
elevation in the CKD patient population Alam, et al. (2013).
Furthermore, the APRN that quantifies patient risk using CKD measures like
eGFR and albuminuria will help to improve cardiovascular disease risk prediction far
beyond traditional risk factors resulting in better metrics as they have already been
measured in most CKD patients Matsushita et al., (2016). Patients with CKD that present
without suspected ACS can present with elevated troponin levels represent a more potent
predictor of mortality Michos, et al. (2014). The APRN, along with nurses and other
members of the healthcare team, should respond appropriately when any patient presents
with symptomology concerning for ACS such as chest pain, shortness of breath, nausea,
vomiting, pain that radiates to the jaw, arm, back, or the epigastric area.
The APRN should position themselves at the bedside to gather the history of the
present illness, background information, and a complete physical examination. The next

33
steps would involve the implementation of diagnostic testing like an EKG, appropriate
lab tests to include Complete Blood Count, Basic Metabolic Profile, Brain Natriuretic
Peptide (BNP), Procalcitonin, Pro Thrombin Time (PT), Partial Thromboplastin Time
(PTT), INR, Creatine Phosphokinase (CPK), C-Reactive Protein (CPK), Arterial Blood
Gas (ABG), as well as developing an appropriate working list of dynamic differential
diagnoses that will cast a wide net to ensure nothing will be overlooked. In many cases,
the above events will be taking place simultaneously to provide the most effective and
appropriate treatment modalities to ensure the best outcome for the patient. At this
crucial point in the patient’s care, it will be up to the APRN and multidisciplinary team to
determine if troponin elevation identifying as true myocyte necrosis, or not the true
mechanism of the myocardial injury if any at all Mohammed & Januzzi, (2010).
Michos, et al. (2014) concluded that patients with CKD without suspected ACS,
were associated with a worse prognosis when accompanied by elevated troponin levels.
More research is needed in regarding the elevated troponin levels in patients with CKD
and should focus on which biomarker is the most appropriate prognosticly for this patient
population. The possibility exists for the APRN to be immersed in this type of research
which would help to increase current knowledge and to upgrade current evidence-based
guidelines. The APRN operates as a change agent to function as a leader, active member
of the multidisciplinary team, and helping to institute measures that will improve overall
outcomes with providing holistic care, discharge planning, follow up appointments, and
the integration of technology in today’s high-tech world.
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Appendix A
Troponin Elevation in Chronic Kidney Disease Patients’
Pre-and Post-Test
1. What is your current level of education?
A. Associates Degree
B. Diploma
C. Bachelor’s Degree
D. Master’s Degree
2. How many years have you been a Nurse?
A. 0-5 Years
B. 6-10 Years
C. 11-15 Years
D. 16-20 Years
E. Over 20 Years
3. How is Chronic Kidney Disease (CKD) diagnosed? Please Select All That Apply
A. Serum BUN and Creatinine Levels
B. Microalbumin level
C. Complete Blood Count
D. Fasting Blood Glucose
E. Renal Ultrasound
4. What is the normal glomerular filtration rate of a healthy adult?
A. > 60 ML/Min
B. < 60 ML/Min
C. < 40 ML/ Min
D. > 50 ML/Min
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5. Which of the following are risk factors for Chronic Kidney Disease (CKD)?
A. Hypertension
B. Diabetes
C. Cardiovascular Disease
D. Familial History of CKD
E. All the above
6. Which of the following are considered signs and symptoms of Acute Coronary
Syndrome?

Please select all that apply.

A. Chest Pain
B. Dizziness or Lightheadedness
C. Nausea
D. Diaphoresis
E. Dyspnea
7. Which of the following are NOT considered risk factors for ACS?
A. Smoking
B. Elevated Cholesterol
C. Hypertension
D. Abnormal Blood Glucose Level
8.

Which of the following values is considered a normal troponin level?
A. < 0.010
B. < 0.03
C.

> 0.414

D.

> 0.003

9. Which of the following is a sign of Chronic Kidney Disease?
A. Foaming, tea colored, bloody cloudy urine
B. Lower Back Pain
C. Low Grade Temperature
D. Yellow colored straw like urine
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10. Which of the following are considered risk factors of Acute Coronary Syndrome?
Select all that apply
A. Hypertension
B. Elevated cholesterol
C. Obesity
D. Smoker
E. Diabetes
11. What does an elevated troponin in the presence of chronic kidney disease with no
other cardiac symptoms such as chest pain, shortness of breath, nausea, vomiting,
diaphoresis, epigastric pain, back pain, or jaw pain most likely indicate?
A. Acute Myocardial infarction
B. Pancreatitis
C. Increase the risk of cardiac mortality
D. Acute Coronary Syndrome
12. What would an elevated troponin in the setting of Acute Coronary Syndrome with
symptoms to include chest pain, shortness of breath, nausea, vomiting, pain with
radiation to the jaw, neck, back or epigastric area most likely indicate?
A. a CKD flare up
B. Require the need for immediate action to include monitoring and further
diagnostic workup
C. Discharge home with PCP follow up
D. Hypertensive emergency
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Appendix B
CNO Support Letter

September 20, 2017

Dear Mr. Sasso,

Thank you for your interest in enhancing the body of knowledge in emergency nursing
and providing our staff with a voluntary opportunity to participate in nursing research.

I am happy to endorse and support your efforts in this project and will be looking forward
to participating in your research and seeing the outcomes of your education regarding
patients with elevated troponin levels with chronic kidney disease without the presence of
acute coronary syndrome. Your efforts in this area are to be commended and are
wholeheartedly supported.

With best regards,

Darcy Abbott, MS, RN, CEN
Director of Emergency Services
Associate Chief Nursing officer
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Appendix C
Kent IRB Letter
TO:

David Sasso, Jr, BSN, RN

FROM.

Kent Hospital Institutional Review Board

PROJECT TITLE:
SUBMISSION TYPE:

Troponin Elevation in Chronic Kidney Disease: An Educational Project
Review

ACTION:
DECISION DATE.

Determination of IRBNetlD 1142738
October 18, 2017

Dear Mr. Sasso,

Thank you for your submission of the above-named project to the Kent
Institutional Review Board.
Dr. Jonathan Gates, Kent IRB Chair, has determined this project is not subject to
Institutional Review Board regulations, as this is a Performance Improvement Project.
Please retain a copy of this correspondence within your records.
If you have any questions, please contact Donna Coppola, Kent Hospital IRB
Coordinator at 401-7377010, extension 31879 or dmcoppola@carene.org. Please include
your project title in all correspondence with this committee.

Jonathan Gates, MD Kent IRB Chair
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Appendix D
Nurse Recruitment Letter
February 10, 2018
Dear Fellow Nurse,
Hello, my name is David J Sasso Jr. I am currently enrolled in the Master of Science
program in Nursing at Rhode Island College. You are being asked to voluntarily
participate in an educational program about nurses’ knowledge of chronically elevated
troponin levels in the setting of chronic kidney disease, and the absence of acute coronary
syndrome. This project is being conducted in conjunction with Dr. Debra Servello who
serves as the primary investigator. You have been identified as a possible participant
because you are employed within the Emergency Department at Kent Hospital.
The format for the education program will be a pre-test which should take no more than
10-15 minutes of your time to complete. The questions on the pre-test will assess your
knowledge about elevated troponin levels in patients with chronic kidney disease without
acute coronary syndrome. The link embedded at the end of this letter will to take you to
the online survey platform.
An educational poster will be placed in the break room and educational pamphlet will be
emailed to your work email with the hope that you will be able to take time out of your
busy day to review the content.
A link to the post test will be emailed to your work email two weeks after the
informational pamphlet was sent. Results from the pre-test and post-test will be
anonymous. Data will be reviewed to assess aggregate knowledge increase. No
individual data will be shared.
Participation in this program is voluntary. If you do participate you will be entered in a
drawing for a gift card in the amount of $25.00. Should you have any questions about
this project, you may feel free to contact me directly via the means provided below, Dr.
Debra Servello directly at dservello@ric.edu, 401-456-9611 or the Rhode Island College
IRB at IRB@ric.edu. Thank you for your time.
Please click this link to be taken directly to the pre-test (Link Inserted Here).
Sincerely,
David J Sasso Jr, BSN, RN
401-255-8003
dsasso_2082@ric.edu
Rhode Island College
Kent Hospital Emergency Department Per Diem RN
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Appendix E
Email Script

Hello, my name is David J Sasso Jr. I am a graduate student at Rhode Island
College. Part of my curriculum requires that I complete a project. I have chosen to
complete an informational program as my project. I created this informational program
in conjunction with the principle investigator Dr. Debra Servello which is geared towards
emergency department nurses. The project is called Troponin Elevation in Chronic
Kidney Disease.
The program will involve you taking a pre-test, reviewing of an informational
pamphlet, and conclude with a post-test. The pre-test will assess your knowledge about
elevated troponins in patients with Chronic Kidney Disease. The pre-test should take you
no longer than 10-15 minutes to complete. Attached to this email is an informational
letter which will provide more information about the project. Please click the attachment
to review the informational letter. Should you decide to participate, clicking the link
embedded in the informational letter will take you to the pre-test.
A link to the post test will be emailed to your work email two weeks after the
informational pamphlet was sent. Results from the pre-test and post-test will be
anonymous. Data will be reviewed to assess aggregate knowledge increase. No
individual data will be shared.
If you choose to participate, you will be entered in a drawing to receive a $ 25.00
gift card. Your participation is voluntary. Results will be anonymous.
Thank you for taking the time to read this email, informational letter, and for your potential
participation.
Sincerely,
David J Sasso Jr BSN, RN
dsasso_2082@email.ric.edu
Rhode Island College
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Appendix F
Elevated Troponin in Chronic Kidney Disease Program Information
•

Chronic kidney disease (CKD) affects more than 30 million Americans with
many going undiagnosed (Centers for Disease Control and Prevention, 2017).

•

CKD is defined as having a decreased Glomerular Filtration Rate of less than
60ml/min or the presence of elevated biomarkers that may indicate kidney
damage for three months or greater (Ozieh, et al. 2017).

•

CKD Pathophysiology is best described as initial hyperfiltration that activates the
RAAS (Renin Angiotensin Aldosterone System) which causes the protein-uria.
Angiotensin II and protein uptake at the tubules causing inflammation and fibrosis
of the glomerulus and the tubules. This leads to a progressive decline in GFR and
more systemic complications occur (Chaudry, 2012)

•

CKD risk factors include Diabetes, High Blood Pressure, Heart Disease, Familial
History of CKD, and Obesity (CDC, 2017).

•

CKD signs and symptoms are generally nonspecific, and most people don’t feel
ill at all (CDC, 2017).

•

Diagnosing CKD is accomplished by checking BUN, Creatinine, and
microalbumin level in urine. A renal ultrasound may also be ordered. (CDC,
2017).

•

Kidney damage is detected as excretion of urinary albumin of greater than 30
mg/day or its equivalent (Rosenberg, 2016).

•

A decreased eGFR and increased proteinuria increase the risk of developing
cardiovascular disease (Sarnack, Gibson & Henrick, 2015).
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•

Patients diagnosed with CKD present with traditional and nontraditional risk
factors that contribute to the development of cardiovascular disease such as
hypertension, smoking, diabetes, and elevated cholesterol levels (Sarnack, Gibson
& Henrick, 2015).

•

Heart disease is the number one cause of death in the CKD patient population
summating up to 50% of deaths Colbert et al., (2015).

•

Miller & Granger (2016) state that the chief complaint of chest pain is responsible
for approximately 6 million annual visits to emergency departments in the United
States. Acute Coronary Syndrome (ACS) is responsible for 12 to 15% of those
cases.

•

Risk factors for ACS include advancing age, elevated blood pressure, elevated
cholesterol, cigarette smoking, lack of physical activity, unhealthy diet, diabetes,
obesity, and known familial history of chest pain, heart disease or stroke. (Mayo
Clinic, 2017)

•

ACS is a functional term applied to patients where there is an indication of
myocardial ischemia or myocardial infarction. (Miller & Granger, 2016)

•

ACS refers to a spectrum of clinical presentations ranging from ST-Segment
elevation myocardial infarction (STEMI) to presentations commonly found in
non-ST Segment elevation infarction (NSETMI) or unstable angina (Coven &
Yang, 2016)

•

There are three different types of ACS: unstable angina, non-ST elevation MI, and
ST segment elevation MI. ST segment elevation and non-ST elevation MI,
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diagnosable if elevated troponin levels are present, which will typically rise and
fall before, during, and after an event. (Miller & Granger, 2016)
•

Patients experiencing ACS may describe their symptoms as palpitations, pain in
the chest described as pressure, squeezing, or a burning sensation primarily in the
precordium with potential radiation to the neck, shoulder, back, upper abdomen,
or either arm. Exertional dyspnea that resolved with pain or rest. Nausea,
Vomiting, or profuse diaphoresis may also be complaints. (Coven & Yang, 2016)

•

Unstable angina is classified as myocardial ischemia with no elevation in
biomarkers like troponin. (Miller & Granger, 2016)

•

The immediate focus should be on treatment, because early intervention leads to
the best outcomes. (Miller & Granger, 2016)

•

Upon presentation to the emergency department, an initial 12 lead EKG should be
obtained within ten minutes, and continuous telemetry monitoring initiated. (Miller
& Granger, 2016)

•

Next, a history and physical exam to correlate with current signs and symptoms
exhibited. Laboratory tests should be ordered, to include troponin, electrolytes,
bun, creatinine, and complete blood count. (Miller & Granger, 2016)

•

A chest x-ray is standard in this patient population, as it can be an asset with
differential diagnosis. A risk stratification assessment of the patient presenting with
these signs and symptoms is conducted. (Miller & Granger, 2016)

•

Troponin is the preferred biomarker to diagnose acute myocardial infarction
which may or may not be present with presentation of ACS. (Januzzi &
Mohammed, 2010)
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•

Troponin is a macromolecular complex that consists of three polypeptides closely
intertwined and are actively related to the contraction of heart muscle. (Januzzi &
Mohammed, 2010)

•

A normal troponin level is < 0.03 as referenced Januzzi & Mohommad, 2010

•

Michos (2014) Elevated troponin levels reveal an association of a worse
prognosis in patients with CKD not experiencing ACS. For patients with CKD
with no indication of ACS, elevated troponin levels remain potent predictors of
mortality, and currently support the current U.S. Food and Drug Administration
position that measuring serum troponin levels is an appropriate risk stratification
tool in this patient population.

